Ameriprise Financial Inc Cerevel Therapeutics Holdings, Inc. Transaction History

Ameriprise Financial Inc

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$38.96 - $42.75 $30.6 Million - $33.6 Million	784,907 Added 139.47%	1,347,680 $55.1 Million
Q1 2024 May 15, 2024	BUY	$40.88 - $43.27 $22.8 Million - $24.1 Million	557,340 Added 10258.42%	562,773 $23.8 Million
Q4 2023 Feb 14, 2024	BUY	$20.27 - $42.44 $110,126 - $230,576	5,433 New	5,433 $230,000

5.01M

3.3K

Ticker CERE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 155,752,000
Description
Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-...

Get notified when there are updates to the investment portfolio of Ameriprise Financial Inc, based on Form 13F filings with the SEC.

Stay updated on Ameriprise Financial Inc with notifications on news.